Table 4

Immunogenicity of the BNT162b2 messenger RNA vaccine according to the use of immunosuppressive treatments in comparison with controls

Immunosuppressive treatments, nSeropositivity rate, n (%)P value
GC, n=13086 (66)<0.0001
GC monotherapy, n=1310 (77)<0.0001
MTX, n=176148 (84)<0.0001
MTX monotherapy, n=4138 (92)0.02
HCQ, n=133120 (90)0.001
HCQ monotherapy, n=5049 (98)0.65
LEF, n=2825 (89)0.004
LEF monotherapy, n=1111 (100)NA
TNFi, n=172167 (97)0.15
TNFi monotherapy, n=121119 (98)0.48
TNFi +MTX, n=2927 (93)0.04
IL6i, n=3737 (100)NA
IL6i monotherapy, n=1919 (100)NA
IL6i+MTX, n=77 (100)NA
Anti-CD20, n=8736 (41)<0.0001
Anti-CD20 monotherapy, n=2811 (39)<0.0001
Rituximab+MTX, n=145 (36)<0.0001
IL17i, n=4847 (98)0.63
IL17i monotherapy, n=3737 (100)NA
IL17i+MTX, n=76 (85)0.05
Abatacept, n=1610 (62)<0.0001
Abatacept monotherapy, n=75 (71)<0.0001
Abatacept+MTX, n=52 (40)<0.0001
JAKi monotherapy, n=2119 (90)0.02
JAK+MTX, n=2422 (92)0.03
Belimumab, n=97 (77)0.0001
MMF, n=2818 (64)<0.0001
  • anti-CD20, CD20 inhibitors; GC, glucocorticoids; HCQ, hydroxychloroquine; IL6i, interleukin 6 inhibitors; IL17i, interleukin 17 inhibitors; JAKi, Janus kinase inhibitors; LEF, leflunomide; MMF, mycophenolate mofetil; MTX, methotrexate; TNFi, tumour necrosis factor inhibitors.